Compare AbCellera Biologics Inc (ABCL) vs Gold Fields Limited (GFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Gold Fields Limited — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Gold Fields Limited trades at $32.9 (market cap $30.01B). The key difference: Gold Fields Limited is far larger — about 12.8× AbCellera Biologics Inc's market cap, and Gold Fields Limited pays a 6.91% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GFI | |
|---|---|---|
Market Cap | $2.35B | $30.01B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $61.52 |
52-Week Low | $2.78 | $23.36 |
Enterprise Value | $1.99B | $31.46B |
Dividend Yield | — | 6.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Gold Fields (GFI) trades at $33.58, down 5.3% over 24 hours, reflecting recent bearish technical momentum. The stock shows strong fundamentals with a P/E of 8.78 and robust profitability margins, including a 40.76% net income margin. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and the balance sheet remains solid despite rising debt levels. Analyst sentiment is divided with a 44% buy rating amid operational challenges and gold price volatility.
The outlook for GFI hinges on execution at key mines like Salares Norte and gold price stability. Upside potential exists from strong cash generation and shareholder returns, but risks include cost inflation and geopolitical pressures. The current valuation appears attractive if operational targets are met, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
